UK markets closed

Roche Holding AG (0TDF.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
39.98-0.05 (-0.12%)
At close: 03:18PM GMT
Full screen
Previous close40.03
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume10,500
Avg. volumeN/A
Market cap2.723B
Beta (5Y monthly)0.18
PE ratio (TTM)0.19
EPS (TTM)2.07
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Roche Alzheimer’s disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis

    The Elecsys® Alzheimer’s disease (AD) CSF assays will be available on the cobas fully automated immunoassay analyzers, enabling patients to get broad access to high quality testing in a timely manner.Greater accessibility and lower cost means these assays could accelerate the path to diagnosis for people with Alzheimer’s disease.The assays are easily scalable to meet the imminent demand for Alzheimer’s disease modifying therapies as they become available. Basel, 8 December 2022 - Roche (SIX: RO,

  • Zacks

    Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

    Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

  • Reuters

    Roche shutters most trials of Alzheimer's drug after failed trials

    Swiss drugmaker Roche is closing down most clinical trials of its experimental Alzheimer's drug gantenerumab after it failed to slow advance of the mind-robbing disease in a pair of large, late-stage studies, the company said on Wednesday. Roche presented full results of twin trials at an Alzheimer's meeting in San Francisco after announcing in November that the drug had failed in the two trials. Unlike Eisai Co Ltd and Biogen Inc's lecanemab, which appears to be on track for U.S. regulatory approval after presenting successful trial results on Tuesday, Roche's drug did not show a statistically significant benefit in patients with mild cognitive impairment and early Alzheimer's disease.